An interventional study of Self- management program and Standard care in Stroke and Chronic Conditions, sponsored by The University of Texas Medical Branch, Galveston. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by The University of Texas Medical Branch, Galveston · Not applicable, Interventional, and Other
Due to the low number of accruals during the Covid 19 environment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.
Among the 1,995 studies in Stroke with a site in United States, this one is the 969th largest by enrollment of the 1,621 interventional ones that give a count, is one of 117 that started in 2019, is one of 1,124 with no phase, and was the 1,183rd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 40–85
Carle Foundation Hospital · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–79
Neuralink Corp · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,995 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 236 · Phase 3 126 · Phase 4 43
First in 1980; this study’s year is marked. 117 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 40 across the 1,621 interventional studies, 153 across the 363 observational. Of the 1,332 that completed or were terminated, 564 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 1,995 have an industry lead sponsor. The 10 most frequent:
The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 36 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
The University of Texas Medical Branch, Galveston has 9 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
167 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 167 to your calendar (.ics) → With an account.
Among the 1,995 studies in Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke is a leading cause of disability, institutionalization, readmission and death. This research is being completed to accelerate the adoption of evidence-based therapy practices that improve overall stroke care and outcomes. We will implement a feasibility randomized controlled trial (RCT) studying the implementation of a stroke specific chronic disease self-management program. Specifically, if the person is identified to have a chronic vision impairment identified on the vision screen, a specific low vision self-management program will be used. Otherwise the program that will be used is the generic chronic disease self-management program.
Approximately 75% of people are living with a prevalent chronic disease like diabetes or hypertension. Despite this high percentage, there is a projected increase of 37% by 2030. There are approximately 795,000 people sustaining a stroke each year, in the United States. Surviving a stroke can cost an estimated $34 billion dollars a year in medical costs and loss of productivity. While there is a sharp decline in mortality rate following stroke, the rate of long-term residual impairments, disabilities and risk for developing high rates of secondary chronic conditions remains high. People living with a new stroke can also have chronic conditions in their past medical histories. Management of prior and new conditions may not become evident until the stroke survivor has returned to the community and are no longer receiving medical services. Additionally, management of chronic conditions, especially for people who now are recovering from a stroke, may require different management plans altogether. The Center for Disease Control and Prevention called for a public health action to address chronic illness. One type of community rehabilitation intervention method is self-management.
Self-management was first developed for well-elderly with chronic diseases. These programs support individuals managing their independently managing symptoms as well as help with the emotional and physical stress associated with chronic disease. Multiple research reports conclude that self-management interventions improve health outcomes, help with management of self-identity and reduce health care costs.
There are existing stroke specific self-management programs, however minimal reported research regarding the best way to implement and measure a stroke specific chronic disease self-management program to optimize health outcomes and improve quality of life. Recently, a qualitative study concluded that any stroke specific self-management program should include 3 conceptual layers to address individual, external and environmental factors essential to enable successful implementation. The first conceptual layer is individual capacity or readiness to respond to the demands to self-management. The second is having external support for self-management. And the third is being in an environment that supports and facilitates success. Another study reported strong feasibility evidence for stroke specific self-management programs versus a standard program for community dwelling stroke survivors. A small study reported a program administered to stroke patients that led to changes in self-efficacy.
Consistent with a feasibility study for implementing evidence based intervention, this project intends to address a need to bridge the translation gap between research evidence and clinical practice. This project intends to provide information to add to existing literature regarding implementation. Thus we plan to use the Determinant Framework, which will help specify determinants which act as barriers and enablers that influence implementation outcomes. Additionally, implementation theories will help us assess the implementation context, as we plan to use a checklist to evaluate factors influencing implementation across different domains (e.g. fidelity). This study also intends to provide preliminary data regarding efficacy in order to determine if a stroke specific program was superior to standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The standard care group will receive baseline testing #1, standard care, baseline testing #2 and follow up testing approximately 8 weeks later.
Other: Standard care
Experimental group will baseline testing #1, standard care, baseline testing #2 however then participate in a 6-week self-management intervention (either generic or vision specific self-management based) and then get 8 week follow up testing.
Other: Self- management program
The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program. Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks
All stroke patients being discharged from the acute hospital receive the following care: 1. 1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling. 2. A stroke clinic appointment that is set to occur 90-days post discharge. 3. A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included. 4. Information on local support groups. 5. Referrals to start physical, occupational or speech therapy, if recommended by their physician.
Feasibility: Patients Screened
number of patients screened
Time frame: Collected at baseline 1 (24 hours prior to the patients' discharge from acute care)
Feasibility: Eligible Patients
number of patients eligible
Time frame: Collected at baseline 1 (24 hours prior to the patients' discharge from acute care)
Feasibility: Patients Approached
number of patients approached
Time frame: Collected at baseline 1 (24 hours prior to the patients' discharge from acute care)
Feasibility: Patients Enrolled
number of patients enrolled
Time frame: Collected at baseline 1 (24 hours prior to the patients' discharge from acute care)
Feasibility: Patient Refusals
number of patient refusals
Time frame: Collected at follow-up (2 weeks from last day of intervention)
Feasibility: Patient Withdrawals
number of patient withdrawals
Time frame: Collected at follow-up (2 weeks from last day of intervention)
Change in self-reported self-management, as measured by the Southampton Stroke Self-Management Questionnaire
patient-reported outcome measure (PROM) of self-management competency following stroke, likert scale 1-6, higher scores on the scale equal less self-management skills
Time frame: change in self- management from base line 1 (24 hours prior to discharge from acute care) to base line 2 (3 months)
Change in self-reported self-management, as measured by the Southampton Stroke Self-Management Questionnaire
patient-reported outcome measure (PROM) of self-management competency following stroke, likert scale 1-6, higher scores on the scale equal less self-management skills
Time frame: change in self-management from base line 2 (3 months) to follow-up (2 weeks from last day of intervention)
Change in self-reported self-efficacy, as measured by the Patient Reported Outcome Measure Information System (PROMIS) self-efficacy scale
Self-Efficacy for Managing: Daily Activities, Symptoms, Medications and Treatments, Emotions, and Social Interactions. Likert scale 1-5, higher scores on the scale equal better confidence
Time frame: change in self-efficacy from base line 1 (24 hours prior to discharge from acute care), base line 2 (3 months)
Change in self-reported self-efficacy, as measured by the Patient Reported Outcome Measure Information System (PROMIS) self-efficacy scale
Self-Efficacy for Managing: Daily Activities, Symptoms, Medications and Treatments, Emotions, and Social Interactions. Likert scale 1-5, higher scores on the scale equal better confidence
Time frame: change in self-efficacy from base line 2 (3 months) to follow-up (2 weeks from last day of intervention)
Change in self-reported sleep, as measured by the PROMIS sleep disturbance and sleep-related impairments
qualitative aspects of sleep and wake function via Likert scale of 1-5, higher scores on the scale equal better sleep
Time frame: change in sleep from base line 1 (24 hours prior to discharge from acute care), base line 2 (3 months)
Change in self-reported sleep, as measured by the PROMIS sleep disturbance and sleep-related impairments
qualitative aspects of sleep and wake function via Likert scale of 1-5, higher scores on the scale equal better sleep
Time frame: change in sleep from base line 2 (3 months) to follow-up (2 weeks from last day of intervention)
Change in self-reported vision, as measured by the national eye institute vision function questionnaire -25
vision quality of life, likert scale 1-5, higher scores on the scale equal better visual function
Time frame: change in vision quality of life from base line 1 (24 hours prior to discharge from acute care) to base line 2 (3 months)
Change in self-reported vision, as measured by the national eye institute vision function questionnaire -25
vision quality of life, likert scale 1-5, higher scores on the scale equal better visual function
Time frame: change in vision quality of life from base line 2 (3 months) to follow-up (2 weeks from last day of intervention)
Change in self-reported health distress, as measured by the Health Distress Questionnaire
health distress, likert scale 0-5, higher scores on the scale equal more distress.
Time frame: change in health distress from base line 1 (24 hours prior to discharge from acute care) to base line 2 (3 months)
Change in self-reported health distress, as measured by the Health Distress Questionnaire
health distress, likert scale 0-5, higher scores on the scale equal more distress.
Time frame: change in health distress from base line 2 (3 months) to follow-up (2 weeks from last day of intervention)
Plan to share: No
Ran from Sep 2019 to primary completion in Sep 2021, 24 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2021 → Sep 2021 and completion Dec 2022 → Sep 2021.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Due to the low number of accruals during the Covid 19 environment
Due to the low number of accruals during the Covid 19 environment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Medical Branch, Galveston →